|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tsoi KK, Hirai HW, Chan FC, Griffiths S
and Sung JJ: Cancer burden with ageing population in urban regions
in China: Projection on cancer registry data from World Health
Organization. Br Med Bull. 121:83–94. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lieberman D, Ladabaum U, Cruz-Correa M,
Ginsburg C, Inadomi JM, Kim LS, Giardiello FM and Wender RC:
Screening for colorectal cancer and evolving issues for physicians
and patients: A review. JAMA. 316:2135–2145. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arkan MC: Cancer: Fat and the fate of
pancreatic tumours. Nature. 536:157–158. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li S, Xu HX, Wu CT, Wang WQ, Jin W, Gao
HL, Li H, Zhang SR, Xu JZ, Qi ZH, et al: Angiogenesis in pancreatic
cancer: Current research status and clinical implications.
Angiogenesis. Aug 24–2018.(Epub ahead of print).
|
|
7
|
Xu W, Taranets L and Popov N: Regulating
Fbw7 on the road to cancer. Semin Cancer Biol. 36:62–70. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cao J, Ge MH and Ling ZQ: Fbxw7 tumor
suppressor: A vital regulator contributes to human tumorigenesis.
Medicine (Baltimore). 95:e24962016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Davis RJ, Welcker M and Clurman BE: Tumor
suppression by the Fbw7 ubiquitin ligase: Mechanisms and
opportunities. Cancer Cell. 26:455–464. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shimizu K, Nihira NT, Inuzuka H and Wei W:
Physiological functions of FBW7 in cancer and metabolism. Cell
Signal. 46:15–22. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Inuzuka H, Shaik S, Onoyama I, Gao D,
Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, et al:
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for
ubiquitylation and destruction. Nature. 471:104–109. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Davis MA, Larimore EA, Fissel BM, Swanger
J, Taatjes DJ and Clurman BE: The SCF-Fbw7 ubiquitin ligase
degrades MED13 and MED13L and regulates CDK8 module association
with Mediator. Genes Dev. 27:151–156. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Balamurugan K, Sharan S, Klarmann KD,
Zhang Y, Coppola V, Summers GH, Roger T, Morrison DK, Keller JR and
Sterneck E: FBXW7α attenuates inflammatory signalling by
downregulating C/EBPδ and its target gene Tlr4. Nat Commun.
4:16622013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bengoechea-Alonso MT and Ericsson J: Tumor
suppressor Fbxw7 regulates TGFβ signaling by targeting TGIF1 for
degradation. Oncogene. 29:5322–5328. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hao B, Oehlmann S, Sowa ME, Harper JW and
Pavletich NP: Structure of a Fbw7-Skp1-cyclin E complex:
Multisite-phosphorylated substrate recognition by SCF ubiquitin
ligases. Mol Cell. 26:131–143. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Olive V, Sabio E, Bennett MJ, De Jong CS,
Biton A, McGann JC, Greaney SK, Sodir NM, Zhou AY, Balakrishnan A,
et al: A component of the mir-17-92 polycistronic oncomir promotes
oncogene-dependent apoptosis. Elife. 2:e008222013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang L, Ye X, Liu Y, Wei W and Wang Z:
Aberrant regulation of FBW7 in cancer. Oncotarget. 5:2000–2015.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kimura T, Gotoh M, Nakamura Y and Arakawa
H: hCDC4b, a regulator of cyclin E, as a direct transcriptional
target of p53. Cancer Sci. 94:431–436. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ekholm-Reed S, Goldberg MS, Schlossmacher
MG and Reed SI: Parkin-dependent degradation of the F-box protein
Fbw7b promotes neuronal survival in response to oxidative stress by
stabilizing Mcl-1. Mol Cell Biol. 33:3627–3643. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Akhoondi S, Lindström L, Widschwendter M,
Corcoran M, Bergh J, Spruck C, Grandér D and Sangfelt O:
Inactivation of FBXW7/hCDC4-β expression by promoter
hypermethylation is associated with favorable prognosis in primary
breast cancer. Breast Cancer Res. 12:R1052010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Z, Inuzuka H, Zhong J, Wan L,
Fukushima H, Sarkar FH and Wei W: Tumor suppressor functions of
FBW7 in cancer development and progression. FEBS Lett.
586:1409–1418. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu Y, Sengupta T, Kukreja L and Minella
AC: MicroRNA-223 regulates cyclin E activity by modulating
expression of F-box and WD-40 domain protein 7. J Biol Chem.
285:34439–34446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Feng DD, Zhang H, Zhang P, Zheng YS, Zhang
XJ, Han BW, Luo XQ, Xu L, Zhou H, Qu LH, et al: Down-regulated
miR-331-5p and miR-27a are associated with chemotherapy resistance
and relapse in leukemia. J Cell Mol Med. 15:2164–2175. 2010.
View Article : Google Scholar
|
|
25
|
Cheng X, Hao Y, Shu W, Zhao M, Zhao C, Wu
Y, Peng X, Yao P, Xiao D, Qing G, et al: Cell cycle-dependent
degradation of the methyltransferase SETD3 attenuates cell
proliferation and liver tumorigenesis. J Biol Chem. 292:9022–9033.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schülein-Völk C, Wolf E, Zhu J, Xu W,
Taranets L, Hellmann A, Jänicke LA, Diefenbacher ME, Behrens A,
Eilers M, et al: Dual regulation of Fbw7 function and oncogenic
transformation by Usp28. Cell Rep. 9:1099–1109. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sancho R, Blake SM, Tendeng C, Clurman BE,
Lewis J and Behrens A: Fbw7 repression by hes5 creates a feedback
loop that modulates Notch-mediated intestinal and neural stem cell
fate decisions. PLoS Biol. 11:e10015862013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tong J, Tan S, Zou F, Yu J and Zhang L:
FBW7 mutations mediate resistance of colorectal cancer to targeted
therapies by blocking Mcl-1 degradation. Oncogene. 36:787–796.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gong J, Zhou Y, Liu D and Huo J: F-box
proteins involved in cancer-associated drug resistance. Oncol Lett.
15:8891–8900. 2018.PubMed/NCBI
|
|
30
|
Suryo Rahmanto A, Swartling FJ and
Sangfelt O: Targeting SOX9 for degradation to inhibit
chemoresistance, metastatic spread, and recurrence. Mol Cell Oncol.
4:e12528712016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yada M, Hatakeyama S, Kamura T, Nishiyama
M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K and
Nakayama KI: Phosphorylation-dependent degradation of c-Myc is
mediated by the F-box protein Fbw7. EMBO J. 23:2116–2125. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Biswas M, Phan D, Watanabe M and Chan JY:
The Fbw7 tumor suppressor regulates nuclear factor E2-related
factor 1 transcription factor turnover through proteasome-mediated
proteolysis. J Biol Chem. 286:39282–39289. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Welcker M, Larimore EA, Frappier L and
Clurman BE: Nucleolar targeting of the fbw7 ubiquitin ligase by a
pseudosubstrate and glycogen synthase kinase 3. Mol Cell Biol.
31:1214–1224. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lerner M, Lundgren J, Akhoondi S, Jahn A,
Ng HF, Akbari Moqadam F, Oude Vrielink JA, Agami R, Den Boer ML,
Grandér D and Sangfelt O: MiRNA-27a controls FBW7/hCDC4-dependent
cyclin E degradation and cell cycle progression. Cell Cycle.
10:2172–2183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kurashige J, Watanabe M, Iwatsuki M,
Kinoshita K, Saito S, Hiyoshi Y, Kamohara H, Baba Y, Mimori K and
Baba H: Overexpression of microRNA-223 regulates the ubiquitin
ligase FBXW7 in oesophageal squamous cell carcinoma. Br J Cancer.
106:182–188. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li J, Guo Y, Liang X, Sun M, Wang G, De W
and Wu W: MicroRNA-223 functions as an oncogene in human gastric
cancer by targeting FBXW7/hCdc4. J Cancer Res Clin Oncol.
138:763–774. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ma J, Cheng L, Liu H, Zhang J, Shi Y, Zeng
F, Miele L, Sarkar FH, Xia J and Wang Z: Genistein down-regulates
miR-223 expression in pancreatic cancer cells. Curr Drug Targets.
14:1150–1156. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Takada M, Zhang W, Suzuki A, Kuroda TS, Yu
Z, Inuzuka H, Gao D, Wan L, Zhuang M, Hu L, et al: FBW7 loss
promotes chromosomal instability and tumorigenesis via Cyclin
E1/CDK2-mediated phosphorylation of CENP-A. Cancer Res.
77:4881–4893. 2017.PubMed/NCBI
|
|
39
|
Li Y, Hu K, Xiao X, Wu W, Yan H, Chen H,
Chen Z and Yin D: FBW7 suppresses cell proliferation and G2/M cell
cycle transition via promoting γ-catenin K63-linked ubiquitylation.
Biochem Biophys Res Commun. 497:473–479. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ma J, Fang B, Zeng F, Ma C, Pang H, Cheng
L, Shi Y, Wang H, Yin B, Xia J and Wang Z: Down-regulation of
miR-223 reverses epithelial-mesenchymal transition in
gemcitabine-resistant pancreatic cancer cells. Oncotarget.
6:1740–1749. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang Y, Liu H, Hou Y, Zhou X, Liang L,
Zhang Z, Shi H, Xu S, Hu P, Zheng Z, et al: Performance validation
of an amplicon-based targeted next-generation sequencing assay and
mutation profiling of 648 Chinese colorectal cancer patients.
Virchows Arch. 472:959–968. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Iwatsuki M, Mimori K, Ishii H, Yokobori T,
Takatsuno Y, Sato T, Toh H, Onoyama I, Nakayama KI, Baba H and Mori
M: Loss of FBXW7, a cell cycle regulating gene, in colorectal
cancer: Clinical significance. Int J Cancer. 126:1828–1837. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li Q, Li Y, Li J, Ma Y, Dai W, Mo S, Xu Y,
Li X and Cai S: FBW7 suppresses metastasis of colorectal cancer by
inhibiting HIF1α/CEACAM5 functional axis. Int J Biol Sci.
14:726–735. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ou B, Zhao J, Guan S, Wangpu X, Zhu C,
Zong Y, Ma J, Sun J, Zheng M, Feng H and Lu A: Plk2 promotes tumor
growth and inhibits apoptosis by targeting Fbxw7/Cyclin E in
colorectal cancer. Cancer Lett. 380:457–466. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cizmecioglu O, Krause A, Bahtz R, Ehret L,
Malek N and Hoffmann I: Plk2 regulates centriole duplication
through phosphorylation-mediated degradation of Fbxw7 (human Cdc4).
J Cell Sci. 125:981–992. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jung JH, Jung DB, Kim H, Lee H, Kang SE,
Srivastava SK, Yun M and Kim SH: Zinc finger protein 746 promotes
colorectal cancer progression via c-Myc stability mediated by
glycogen synthase kinase 3β and F-box and WD repeat
domain-containing 7. Oncogene. 37:3715–3728. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li L, Sarver AL, Khatri R, Hajeri PB,
Kamenev I, French AJ, Thibodeau SN, Steer CJ and Subramanian S:
Sequential expression of miR-182 and miR-503 cooperatively targets
FBXW7, contributing to the malignant transformation of colon
adenoma to adenocarcinoma. J Pathol. 234:488–501. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Khan OM, Carvalho J, Spencer-Dene B,
Mitter R, Frith D, Snijders AP, Wood SA and Behrens A: The
deubiquitinase USP9X regulates FBW7 stability and suppresses
colorectal cancer. J Clin Invest. 128:1326–1337. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fang L, Yang Z, Zhou J, Tung JY, Hsiao CD,
Wang L, Deng Y, Wang P, Wang J and Lee MH: Circadian clock gene
CRY2 degradation is involved in chemoresistance of colorectal
cancer. Mol Cancer Ther. 14:1476–1487. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Imura S, Tovuu LO, Utsunomiya T, Morine Y,
Ikemoto T, Arakawa Y, Kanamoto M, Iwahashi S, Saito Y, Takasu C, et
al: The role of Fbxw7 expression in hepatocellular carcinoma and
adjacent non-tumor liver tissue. J Gastroenterol Hepatol.
29:1822–1829. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang X, Zhang J, Zhou L, Sun W, Zheng ZG,
Lu P, Gao Y, Yang XS, Zhang ZC, Tao KS and Dou KF: Fbxw7 regulates
hepatocellular carcinoma migration and invasion via Notch1
signaling pathway. Int J Oncol. 47:231–243. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chen J, Wang H, Wang J, Huang S and Zhang
W: STAT1 inhibits human hepatocellular carcinoma cell growth
through induction of p53 and Fbxw7. Cancer Cell Int. 15:1112015.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang Y, Liu Z, Yao B, Li Q, Wang L, Wang
C, Dou C, Xu M, Liu Q and Tu K: Long non-coding RNA CASC2
suppresses epithelial-mesenchymal transition of hepatocellular
carcinoma cells through CASC2/miR-367/FBXW7 axis. Mol Cancer.
16:1232017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yu J, Zhang W, Gao F, Liu YX, Chen ZY,
Cheng LY, Xie SF and Zheng SS: FBW7 increases chemosensitivity in
hepatocellular carcinoma cells through suppression of
epithelial-mesenchymal transition. Hepatobiliary Pancreat Dis Int.
13:184–191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zheng M, Xu H, Liao XH, Chen CP, Zhang AL,
Lu W, Wang L, Yang D, Wang J, Liu H, et al: Inhibition of the
prolyl isomerase Pin1 enhances the ability of sorafenib to induce
cell death and inhibit tumor growth in hepatocellular carcinoma.
Oncotarget. 8:29771–29784. 2017.PubMed/NCBI
|
|
56
|
Lee JW, Soung YH, Kim HJ, Park WS, Nam SW,
Kim SH, Lee JY, Yoo NJ and Lee SH: Mutational analysis of the hCDC4
gene in gastric carcinomas. Eur J Cancer. 42:2369–2373. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Jiang Y, Qi X, Liu X, Zhang J, Ji J, Zhu
Z, Ren J and Yu Y: Fbxw7 haploinsufficiency loses its protection
against DNA damage and accelerates MNU-induced gastric
carcinogenesis. Oncotarget. 8:33444–33456. 2017.PubMed/NCBI
|
|
58
|
Li MR, Zhu CC, Ling TL, Zhang YQ, Xu J,
Zhao EH and Zhao G: FBXW7 expression is associated with prognosis
and chemotherapeutic outcome in Chinese patients with gastric
adenocarcinoma. BMC Gastroenterol. 17:602017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yokobori T, Mimori K, Iwatsuki M, Ishii H,
Onoyama I, Fukagawa T, Kuwano H, Nakayama KI and Mori M:
p53-Altered FBXW7 expression determines poor prognosis in gastric
cancer cases. Cancer Res. 69:3788–3794. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Li H, Wang Z, Zhang W, Qian K, Xu W and
Zhang S: Fbxw7 regulates tumor apoptosis, growth arrest and the
epithelial-to-mesenchymal transition in part through the RhoA
signaling pathway in gastric cancer. Cancer Lett. 370:39–55. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhou X, Jin W, Jia H, Yan J and Zhang G:
MiR-223 promotes the cisplatin resistance of human gastric cancer
cells via regulating cell cycle by targeting FBXW7. J Exp Clin
Cancer Res. 34:282015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Eto K, Iwatsuki M, Watanabe M, Ishimoto T,
Ida S, Imamura Y, Iwagami S, Baba Y, Sakamoto Y, Miyamoto Y, et al:
The sensitivity of gastric cancer to trastuzumab is regulated by
the miR-223/FBXW7 pathway. Int J Cancer. 136:1537–1545. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Naganawa Y, Ishiguro H, Kuwabara Y, Kimura
M, Mitsui A, Katada T, Tanaka T, Shiozaki M, Fujii Y and Takeyama
H: Decreased expression of FBXW7 is correlated with poor prognosis
in patients with esophageal squamous cell carcinoma. Exp Ther Med.
1:841–846. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yokobori T, Mimori K, Iwatsuki M, Ishii H,
Tanaka F, Sato T, Toh H, Sudo T, Iwaya T, Tanaka Y, et al: Copy
number loss of FBXW7 is related to gene expression and poor
prognosis in esophageal squamous cell carcinoma. Int J Oncol.
41:253–259. 2012.PubMed/NCBI
|
|
65
|
Er TK, Wang YY, Chen CC,
Herreros-Villanueva M, Liu TC and Yuan SS: Molecular
characterization of oral squamous cell carcinoma using targeted
next-generation sequencing. Oral Dis. 21:872–878. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Arita H, Nagata M, Yoshida R, Matsuoka Y,
Hirosue A, Kawahara K, Sakata J, Nakashima H, Kojima T, Toya R, et
al: FBXW7 expression affects the response to chemoradiotherapy and
overall survival among patients with oral squamous cell carcinoma:
A single-center retrospective study. Tumour Biol. Oct 26–2017.(Epub
ahead of print). doi: 1010428317731771, 2017. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Hua Y, Zhao K, Tao G, Dai C and Su Y:
miR-25 promotes metastasis via targeting FBXW7 in esophageal
squamous cell carcinoma. Oncol Rep. 38:3030–3038. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Calhoun ES, Jones JB, Ashfaq R, Adsay V,
Baker SJ, Valentine V, Hempen PM, Hilgers W, Yeo CJ, Hruban RH and
Kern SE: BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in
distinct subsets of pancreatic cancer: Potential therapeutic
targets. Am J Pathol. 163:1255–1260. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Gao J, Azmi AS, Aboukameel A, Kauffman M,
Shacham S, Abou-Samra AB and Mohammad RM: Nuclear retention of Fbw7
by specific inhibitors of nuclear export leads to Notch1
degradation in pancreatic cancer. Oncotarget. 5:3444–3454. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Jiang JX, Sun CY, Tian S, Yu C, Chen MY
and Zhang H: Tumor suppressor Fbxw7 antagonizes WNT signaling by
targeting β-catenin for degradation in pancreatic cancer. Tumour
Biol. 37:13893–13902. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Ji S, Qin Y, Liang C, Huang R, Shi S, Liu
J, Jin K, Liang D, Xu W, Zhang B, et al: FBW7 (F-box and WD Repeat
Domain-Containing 7) negatively regulates glucose metabolism by
targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) axis in
pancreatic cancer. Clin Cancer Res. 22:3950–3960. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Hu Q, Qin Y, Zhang B, Liang C, Ji S, Shi
S, Xu W, Xiang J, Liang D, Ni Q, et al: FBW7 increases the
chemosensitivity of pancreatic cancer cells to gemcitabine through
upregulation of ENT1. Oncol Rep. 38:2069–2077. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ji S, Qin Y, Shi S, Liu X, Hu H, Zhou H,
Gao J, Zhang B, Xu W, Liu J, et al: ERK kinase phosphorylates and
destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell
Res. 25:561–573. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
He D, Huang C, Zhou Q, Liu D, Xiong L,
Xiang H, Ma G and Zhang Z: HnRNPK/miR-223/FBXW7 feedback cascade
promotes pancreatic cancer cell growth and invasion. Oncotarget.
8:20165–20178. 2017.PubMed/NCBI
|
|
75
|
Yu HG, Wei W, Xia LH, Han WL, Zhao P, Wu
SJ, Li WD and Chen W: FBW7 upregulation enhances cisplatin
cytotoxicity in non-small cell lung cancer cells. Asian Pac J
Cancer Prev. 14:6321–6326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Ye M, Zhang Y, Zhang X and Zhang J, Jing
P, Cao L, Li N, Li X, Yao L and Zhang J and Zhang J: Targeting FBW7
as a strategy to overcome resistance to targeted therapy in
non-small cell lung cancer. Cancer Res. 77:3527–3539. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Lin J, Ji A, Qiu G, Feng H, Li J, Li S,
Zou Y, Cui Y, Song C, He H and Lu Y: FBW7 is associated with
prognosis, inhibits malignancies and enhances temozolomide
sensitivity in glioblastoma cells. Cancer Sci. 109:1001–1011. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Takada M, Zhuang M, Inuzuka H, Zhang J,
Zurlo G, Zhang J and Zhang Q: EglN2 contributes to triple negative
breast tumorigenesis by functioning as a substrate for the FBW7
tumor suppressor. Oncotarget. 8:6787–6795. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Yao S, Xu F, Chen Y, Ge Y, Zhang F, Huang
H, Li L, Lin D, Luo X, Xu J, et al: Fbw7 regulates apoptosis in
activated B-cell like diffuse large B-cell lymphoma by targeting
Stat3 for ubiquitylation and degradation. J Exp Clin Cancer Res.
36:102017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Liang Y, Dong B, Shen J, Ma C and Ma Z:
Clinical significance of bromodomain-containing protein 7 and its
association with tumor progression in prostate cancer. Oncol Lett.
17:849–856. 2019.PubMed/NCBI
|
|
81
|
Niu W, Luo Y, Wang X, Zhou Y, Li H, Wang
H, Fu Y, Liu S, Yin S, Li J, et al: BRD7 inhibits the Warburg
effect and tumor progression through inactivation of HIF1α/LDHA
axis in breast cancer. Cell Death Dis. 9:5192018. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Liu Y, Zhao R, Wei Y, Li M, Wang H, Niu W,
Zhou Y, Qiu Y, Fan S, Zhan Y, et al: BRD7 expression and c-Myc
activation forms a double-negative feedback loop that controls the
cell proliferation and tumor growth of nasopharyngeal carcinoma by
targeting oncogenic miR-141. J Exp Clin Cancer Res. 37:642018.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Yu X, Li Z and Shen J: BRD7: A novel tumor
suppressor gene in different cancers. Am J Transl Res. 8:742–748.
2016.PubMed/NCBI
|
|
84
|
Jin X, Yang C, Fan P, Xiao J, Zhang W,
Zhan S, Liu T, Wang D and Wu H: CDK5/FBW7-dependent ubiquitination
and degradation of EZH2 inhibits pancreatic cancer cell migration
and invasion. J Biol Chem. 292:6269–6280. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Arabi A, Ullah K, Branca RM, Johansson J,
Bandarra D, Haneklaus M, Fu J, Ariës I, Nilsson P, Den Boer ML, et
al: Proteomic screen reveals Fbw7 as a modulator of the NF-κB
pathway. Nat Commun. 3:9762012. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Zeligs KP, Neuman MK and Annunziata CM:
Molecular pathways: The balance between cancer and the immune
system challenges the therapeutic specificity of targeting nuclear
Factor-κB signaling for cancer treatment. Clin Cancer Res.
22:4302–4308. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Chang CC, Lin HH, Lin JK, Lin CC, Lan YT,
Wang HS, Yang SH, Chen WS, Lin TC, Jiang JK and Chang SC: FBXW7
mutation analysis and its correlation with clinicopathological
features and prognosis in colorectal cancer patients. Int J Biol
Markers. 30:e88–e95. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Tu K, Zheng X, Zan X, Han S, Yao Y and Liu
Q: Evaluation of Fbxw7 expression and its correlation with the
expression of c-Myc, cyclin E and p53 in human hepatocellular
carcinoma. Hepatol Res. 42:904–910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Enkhbold C, Utsunomiya T, Morine Y, Imura
S, Ikemoto T, Arakawa Y, Kanamoto M, Iwahashi S, Saito Y, Ishikawa
D and Shimada M: Loss of FBXW7 expression is associated with poor
prognosis in intrahepatic cholangiocarcinoma. Hepatol Res.
44:E346–E352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Ishii N, Araki K, Yokobori T, Gantumur D,
Yamanaka T, Altan B, Tsukagoshi M, Igarashi T, Watanabe A, Kubo N,
et al: Reduced FBXW7 expression in pancreatic cancer correlates
with poor prognosis and chemotherapeutic resistance via
accumulation of MCL1. Oncotarget. 8:112636–112646. 2017. View Article : Google Scholar : PubMed/NCBI
|
